In a Geneva Basement, the Woman Who Counts the Next Pandemic

On the third floor of the World Health Organization's headquarters in Geneva, in a room that smells faintly of disinfectant and recycled air, Dr. Sylvie Briand keeps a map. It is not on the wall. It is on her computer screen, refreshed every six hours, and it shows every documented case of avian influenza A(H5N1) in mammals in the past eighteen months. The dots are color-coded. Red means spillover in wild animals. Orange means spillover in farmed animals. Purple means human infection. On this particular Monday in April 2026, there are 847 red dots, 203 orange dots, and 36 purple dots. Three of the purple dots appeared in the past week. Two are in Vietnam. One is in Egypt. None of them, she tells me, should be there.

Briand is 58, precise in manner, with short grey hair and reading glasses that hang on a beaded chain around her neck. She has directed WHO's pandemic and epidemic preparedness division since 2009, which means she has been the person tracking emerging pathogens longer than anyone else in the building. She was here for H1N1 in 2009, for Ebola in West Africa in 2014, for Zika in 2016, for COVID-19 in 2020. She does not use the word "apocalyptic." She uses the word "plausible."

The purple dots, she explains, represent confirmed human cases of H5N1 — the highly pathogenic avian influenza that has been circulating in wild birds since 1996 but has recently achieved something unprecedented: sustained transmission in mammals. Not just sporadic spillovers, but chains of infection moving through mink farms in Spain, through seal colonies in Peru, through dairy cattle in Texas. And now, sporadically, into humans. The mortality rate in confirmed human cases since 2003 has been 52 percent. The number that keeps Briand awake at night is not the mortality rate. It is the mutation rate in the virus's hemagglutinin gene, which determines whether it can bind efficiently to human respiratory cells. In samples collected from a dairy worker in Texas in March 2026, that gene had accumulated four substitutions not seen in previous strains. Four substitutions is not enough. But it is closer than it was.

The Map She Built

Briand grew up in Lyon, the daughter of a microbiologist and a schoolteacher. She studied epidemiology at the Institut Pasteur in Paris, then joined the French Ministry of Health's infectious disease surveillance unit in 1995. She was there for the BSE crisis, for the first outbreaks of West Nile virus in Europe, for the earliest warnings about SARS. In 2003, she was recruited to WHO to help build its Global Outbreak Alert and Response Network — the system that is supposed to detect and contain emerging pathogens before they become pandemics. She has spent the past 23 years refining that system. She knows, with uncomfortable precision, where it works and where it does not.

The map on her screen is fed by a network of 758 national influenza centers in 128 countries, which are supposed to report every detected case of novel influenza strains to WHO within 24 hours under the International Health Regulations of 2005. In practice, compliance is uneven. Wealthier countries with robust surveillance systems — the United States, the United Kingdom, Japan, Australia — report promptly and comprehensively. Middle-income countries with strained public health infrastructure report sporadically. Low-income countries, particularly in sub-Saharan Africa and parts of Southeast Asia, often do not report at all, not because they are hiding outbreaks, but because they lack the laboratory capacity to detect them in the first place.

Briand opens a second window on her screen. It shows a different map, this one tracking not confirmed cases but "signals" — unverified reports from news media, social media, ProMED-mail, and informal networks of veterinarians and wildlife biologists. The signals map is covered in dots. There are thousands of them, scattered across every continent except Antarctica. Most are false positives: seasonal flu in chickens, botulism in waterfowl, routine mortality events misidentified by panicked farmers. But buried in the noise are the real warnings. In February 2020, three weeks before COVID-19 was declared a pandemic, a signal appeared on this map from a Wuhan hospital reporting an unusual cluster of severe pneumonia cases. Briand's team flagged it. By the time WHO investigators arrived, 41 cases had become 400.

"We were not too late," she says. "We were exactly on time. The problem is that 'on time' for an outbreak means you already have community transmission."

What H5N1 Is Doing Now

The current wave of H5N1 began in October 2021, when a novel clade — designated 2.3.4.4b by the WHO nomenclature system — emerged in wild waterfowl populations in Europe. By January 2022, it had spread to North America. By mid-2022, it had reached South America. By 2023, it was in Antarctica. This is not unusual; avian influenza viruses circulate globally in migratory bird populations every year. What is unusual is the scale of mammalian spillover. Between January 2022 and April 2026, H5N1 has been detected in 47 mammal species, including species that have never before been documented with avian influenza: harbor seals, bottlenose dolphins, mountain lions, brown bears, domestic cats, and — most alarmingly — dairy cattle.

The dairy cattle cases emerged in March 2024 in Texas and Kansas, then spread to 12 other U.S. states. As of April 2026, more than 80 herds have been affected. Unlike in birds, where infection causes rapid death, cattle infected with H5N1 experience reduced milk production, lethargy, and respiratory distress but often survive. This creates what virologists call a "mixing vessel" — an environment where the virus can replicate for extended periods, accumulating mutations, potentially recombining with human seasonal influenza strains if a farmworker is co-infected. It is precisely the scenario that preceded the 1918 influenza pandemic, which is believed to have originated in pigs or birds and acquired the ability to spread efficiently among humans through reassortment.

The 36 confirmed human cases since January 2023 have all been traced to direct contact with infected birds or cattle — farmworkers, poultry cullers, veterinarians. There has been no confirmed human-to-human transmission. But in Vietnam in March 2026, two cases appeared within the same household: a 34-year-old man who worked on a poultry farm, and his 29-year-old wife, who did not. Genetic sequencing showed identical viral strains. WHO investigators concluded the wife likely contracted the virus through close contact with her husband during the early symptomatic phase, not from environmental exposure. The investigation report, obtained by The Editorial, describes this as "probable limited human-to-human transmission" — the exact phrasing used in early SARS reports in 2003.

The Treaty That Isn't Happening

In December 2021, in the aftermath of COVID-19, the World Health Assembly — WHO's governing body, comprising health ministers from all 194 member states — voted to negotiate a Pandemic Accord, a legally binding treaty designed to prevent the next pandemic. The accord was supposed to establish binding commitments on surveillance, pathogen sharing, equitable vaccine distribution, and financing for pandemic preparedness in low-income countries. Negotiators set a deadline of May 2024 for finalization. That deadline passed. A revised deadline of May 2025 also passed. As of April 2026, the accord remains unsigned.

The sticking points are threefold. First, pathogen sharing: several African and Southeast Asian countries refuse to share viral samples with WHO unless they receive guaranteed access to vaccines and treatments derived from those samples. This is a legacy of the 2009 H1N1 pandemic, when Indonesia shared samples of a novel influenza strain, only to watch Western pharmaceutical companies develop vaccines that Indonesia could not afford. Second, intellectual property: India, South Africa, and a bloc of 47 low-income countries demand that the accord include automatic patent waivers for pandemic-related medical products. The United States, Switzerland, and Japan — home to the world's largest pharmaceutical companies — refuse. Third, financing: WHO estimates that achieving basic pandemic preparedness globally would require $31 billion per year. High-income countries have committed $4.7 billion.

Briand attended the most recent negotiating session in February 2026. It lasted four days. On the second day, the U.S. delegation walked out after a proposal to create a WHO-managed stockpile of mRNA vaccine technology was introduced. On the third day, the Chinese delegation objected to provisions requiring real-time disclosure of laboratory biosafety incidents, calling them "intrusive" and "politically motivated." On the fourth day, negotiators agreed to schedule another session in September.

"They are negotiating as if we have time," Briand says. "We do not have time."

The Laboratories That Worry Her Most

There are 59 BSL-4 laboratories in the world — the highest biosafety level, designed for work with the most dangerous pathogens. Briand has visited 22 of them. She describes three categories. The first: state-of-the-art facilities with rigorous protocols, independent oversight, and transparent incident reporting — the U.S. Centers for Disease Control in Atlanta, the Australian Centre for Disease Preparedness in Geelong, the Robert Koch Institute in Berlin. The second: well-equipped facilities with competent staff but limited oversight and inconsistent incident reporting — laboratories in Russia, China, India, Pakistan. The third: facilities that should not exist — laboratories in countries with inadequate regulatory frameworks, insufficient training, or political interference in scientific operations.

She will not name the third category on the record. Off the record, she shows me a list. It includes laboratories in five countries. Two are in Central Asia. One is in the Middle East. Two are in sub-Saharan Africa. All five have reported handling highly pathogenic avian influenza samples. None have reported biosafety incidents to WHO, despite a global survey by the Johns Hopkins Center for Health Security in 2023 estimating that laboratory-acquired infections occur in approximately 1 in every 1,000 person-years of high-risk pathogen research. Statistically, that means at least one laboratory-acquired infection has likely occurred in those five facilities in the past three years.

The proposed Pandemic Accord includes a provision requiring all laboratories handling potential pandemic pathogens to report biosafety incidents within 24 hours and submit to periodic WHO inspections. It has been opposed by 14 countries, including China, Russia, India, Pakistan, Egypt, and Brazil, on grounds of national sovereignty. An alternative proposal — voluntary reporting with no penalties for non-compliance — has been supported by 27 countries but is considered unenforceable by biosafety experts.

The Calculation She Runs Every Week

Every Monday morning, Briand receives a report from WHO's influenza genetics team in London. The report analyzes sequence data from every H5N1 sample collected in the previous week, looking for specific mutations in eight key genes: hemagglutinin (which determines receptor binding), neuraminidase (which facilitates viral release), and the six genes encoding the virus's internal machinery. The mutations that matter are those associated with increased human transmission, based on experiments conducted under strict biosafety protocols in laboratories in the United States, the Netherlands, and Japan between 2011 and 2014. Those experiments — known as "gain-of-function" research — deliberately introduced mutations into H5N1 to identify which changes would allow the virus to spread via respiratory droplets in ferrets, the standard animal model for human influenza transmission.

The experiments identified five critical mutations. As of April 2026, wild H5N1 strains have independently acquired three of them. The Texas dairy worker sample from March contained four. The Vietnamese household transmission cases in March showed three, but in a different combination. Briand runs a calculation: if current mutation rates continue, and if mammalian spillover continues at the current pace, the probability of a fully transmissible human-adapted strain emerging within the next 24 months is approximately 18 percent. That is not a prediction. It is a risk estimate. It is also, she notes, higher than the risk estimate for SARS-CoV-2 spillover in late 2019, which retrospective modeling suggests was around 9 percent.

"We are watching this happen in slow motion," she says. "The difference from COVID is that we can see it coming. The question is whether that makes any difference at all."

The Folder She Has Not Opened

On the shelf behind Briand's desk, next to a stack of WHO situation reports and a photograph of her two daughters, sits a blue folder labeled "1918." It contains photocopies of mortality records from the 1918 influenza pandemic, which killed an estimated 50 to 100 million people worldwide — more than the total combat deaths in World War I and World War II combined. The records are from Lyon, her hometown. In November 1918, the city's hospitals recorded 847 deaths in a single week, most of them in people under 40. The city's normal weekly death rate was 62.

Briand keeps the folder as a reminder of scale. The 1918 virus had an estimated case fatality rate of 2 to 3 percent — low by historical standards, but it infected an estimated 500 million people, roughly one-third of the global population at the time. H5N1's current case fatality rate in humans is 47 to 53 percent, depending on the dataset. If a human-adapted strain emerged with even a fraction of that lethality, and achieved the transmissibility of seasonal influenza, the death toll would be measured in tens of millions within the first year. This is not speculation. It is epidemiological modeling, published in peer-reviewed journals, using conservative assumptions about transmission dynamics and healthcare capacity.

She opens the folder. The mortality records are handwritten in faded ink on yellowed paper. She points to a single line: "Marie Briand, age 28, died 14 November 1918." Her great-grandmother. She survived four years of war. She did not survive the pandemic.

"This is what we are trying to prevent," Briand says. "Not the virus. The virus will do what it does. We are trying to prevent the delay. Every pandemic in history has followed the same pattern: the pathogen emerges, and then we wait. We wait for political consensus, for funding, for vaccines, for coordination. The waiting is what kills people. And we are waiting again."

Outside her office, Geneva is bright with spring. Lake Léman is calm. The swans are back. Somewhere in the reeds, carried by birds whose migrations span continents, a virus is mutating. Briand closes the folder. She returns to the map.